KRAS and cancer: In addition, LKB1 and KEAP1/NRF2 pathways synergistically promote metabolic reprogramming toward enhanced glutamine dependence in lung adenocarcinoma with mutated KRAS, and they also enhance the sensitivity of cancer cells to CB-839 (GLS inhibitor) in vitro and in vivo (165).